Skip to content
Peptigraph home
Shop Peptides50% off*

Is retatrutide a GLP-1?

Partly. Retatrutide does act on the GLP-1 receptor, but it also acts on the GIP and glucagon receptors, which is why it is described as a triple agonist and not a plain GLP-1 drug.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Partly. Retatrutide does act on the GLP-1 receptor, but it also acts on the GIP and glucagon receptors, which is why it is described as a triple agonist and not a plain GLP-1 drug.[1]

A meta-analysis separates GLP-1/glucagon dual agonists from GIP-containing agents and places retatrutide in the second group, with tirzepatide.[2]

Where it sits in the GLP-1 family

A review of incretin peptides lists retatrutide under triple GLP-1/GIP/glucagon agonists, a separate row from the dual GLP-1/glucagon agonists such as survodutide.[3]

The authors of the diabetes trial in adults with obesity said its safety profile was generally consistent with other molecules that have GLP-1 receptor agonism.[4]

A commentary on early diabetes-trial data described the drug's rise in heart rate as consistent with GLP-1 receptor agonism.[5]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

How it worksTarget, mechanism and how long it acts, from the label or studies.Retatrutide overview

Sources

  1. 1[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?].Der Nervenarzt · 2025PMID 40042613Accessed 2 Oct 2026
  2. 2Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.Diabetes, obesity & metabolism · 2026PMID 42811393Accessed 2 Oct 2026
  3. 3Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides · 2025PMID 40081498Accessed 2 Oct 2026
  4. 4Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.Lancet (London, England) · 2026PMID 42810372Accessed 2 Oct 2026
  5. 5Retatrutide showing promise in obesity (and type 2 diabetes).Expert opinion on investigational drugs · 2023PMID 37947489Accessed 2 Oct 2026

Found an error? Report a correction.